Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Gains from Investment Securities (2016 - 2024)

Utah Medical Products (UTMD) has 14 years of Gains from Investment Securities data on record, last reported at $98000.0 in Q4 2024.

  • For Q4 2024, Gains from Investment Securities rose 16.67% year-over-year to $98000.0; the TTM value through Dec 2024 reached $98000.0, up 16.67%, while the annual FY2024 figure was $98000.0, 16.67% up from the prior year.
  • Gains from Investment Securities reached $98000.0 in Q4 2024 per UTMD's latest filing, up from $84000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $98000.0 in Q4 2024 and bottomed at $52000.0 in Q4 2021.
  • Average Gains from Investment Securities over 5 years is $74000.0, with a median of $69000.0 recorded in 2020.
  • Peak YoY movement for Gains from Investment Securities: soared 32.69% in 2020, then fell 24.64% in 2021.
  • A 5-year view of Gains from Investment Securities shows it stood at $69000.0 in 2020, then dropped by 24.64% to $52000.0 in 2021, then grew by 28.85% to $67000.0 in 2022, then increased by 25.37% to $84000.0 in 2023, then grew by 16.67% to $98000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $98000.0 in Q4 2024, $84000.0 in Q4 2023, and $67000.0 in Q4 2022.